Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

A. W. Tolcher, Kenneth H Cowan, D. Solomon, F. Ognibene, B. Goldspiel, R. Chang, M. H. Noone, A. M. Denicoff, C. S. Barnes, M. R. Gossard, P. A. Fetsch, S. L. Berg, F. M. Balis, D. J. Venzon, J. A. O'Shaughnessy

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Purpose: We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) and r-verapamil, the less cardiotoxic stereoisomer, in heavily pretreated patients with metastatic breast cancer. Patients and Methods: Twenty-nine patients refractory to paclitaxel by 3-hour infusion were treated orally with r- verapamil every 4 hours starting 24 hours before the same-dose 3-hour paclitaxel infusion and continuing far a total of 12 doses. Once the maximum- tolerated dose (MTD) of the combination was determined, seven additional patients who had not been treated with either drug were evaluated to determine whether the addition of r-verapamil altered the pharmacokinetics of paclitaxel. Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression before receiving paclitaxel and after becoming refractory to paclitaxel therapy. Results: The MTD of the combination was 225 mg/m2 of r- verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion. Dose- limiting hypotension and bradycardia were observed in three of five patients treated at 250 mg/m2 r-verapamil. Fourteen patients received 32 cycles of r- verapamil at the MTD as outpatient therapy without developing cardiac toxicity. The median peak and trough serum verapamil concentrations at the MTD were 5.1 μmol/L (range, 4.1 to 12.7) and 3.2 μmol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR). Increased serum verapamil concentrations and cardiac toxicity were observed more frequently in patients with elevated hepatic transaminases and bilirubin levels. Hematologic toxicity from combined paclitaxel and r-verapamil was significantly worse compared with the previous cycle of paclitaxel without r- verapamil. In the pharmacokinetic analysis, r-verapamil delayed mean paclitaxel clearance and increased mean peak paclitaxel concentrations. Conclusion: r-Verapamil at 225 mg/m2 orally every 4 hours can be given safely with paclitaxel 200 mg/m2 by 3-hour infusion as outpatient therapy and is associated with serum levels considered active for Pgp inhibition. The addition of r-verapamil significantly alters the toxicity and pharmacokinetics of paclitaxel.

Original languageEnglish (US)
Pages (from-to)1173-1184
Number of pages12
JournalJournal of Clinical Oncology
Volume14
Issue number4
DOIs
StatePublished - Jan 1 1996

Fingerprint

Verapamil
Paclitaxel
Cross-Over Studies
Breast Neoplasms
Maximum Tolerated Dose
P-Glycoprotein
Pharmacokinetics
Home Infusion Therapy
Serum
Stereoisomerism
Multiple Drug Resistance
Bradycardia
Transaminases
Bilirubin
Hypotension
Outpatients

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tolcher, A. W., Cowan, K. H., Solomon, D., Ognibene, F., Goldspiel, B., Chang, R., ... O'Shaughnessy, J. A. (1996). Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. Journal of Clinical Oncology, 14(4), 1173-1184. https://doi.org/10.1200/JCO.1996.14.4.1173

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. / Tolcher, A. W.; Cowan, Kenneth H; Solomon, D.; Ognibene, F.; Goldspiel, B.; Chang, R.; Noone, M. H.; Denicoff, A. M.; Barnes, C. S.; Gossard, M. R.; Fetsch, P. A.; Berg, S. L.; Balis, F. M.; Venzon, D. J.; O'Shaughnessy, J. A.

In: Journal of Clinical Oncology, Vol. 14, No. 4, 01.01.1996, p. 1173-1184.

Research output: Contribution to journalArticle

Tolcher, AW, Cowan, KH, Solomon, D, Ognibene, F, Goldspiel, B, Chang, R, Noone, MH, Denicoff, AM, Barnes, CS, Gossard, MR, Fetsch, PA, Berg, SL, Balis, FM, Venzon, DJ & O'Shaughnessy, JA 1996, 'Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer', Journal of Clinical Oncology, vol. 14, no. 4, pp. 1173-1184. https://doi.org/10.1200/JCO.1996.14.4.1173
Tolcher, A. W. ; Cowan, Kenneth H ; Solomon, D. ; Ognibene, F. ; Goldspiel, B. ; Chang, R. ; Noone, M. H. ; Denicoff, A. M. ; Barnes, C. S. ; Gossard, M. R. ; Fetsch, P. A. ; Berg, S. L. ; Balis, F. M. ; Venzon, D. J. ; O'Shaughnessy, J. A. / Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. In: Journal of Clinical Oncology. 1996 ; Vol. 14, No. 4. pp. 1173-1184.
@article{cb8ed1ac08ef45ef87c1006df3f8b1cd,
title = "Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer",
abstract = "Purpose: We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) and r-verapamil, the less cardiotoxic stereoisomer, in heavily pretreated patients with metastatic breast cancer. Patients and Methods: Twenty-nine patients refractory to paclitaxel by 3-hour infusion were treated orally with r- verapamil every 4 hours starting 24 hours before the same-dose 3-hour paclitaxel infusion and continuing far a total of 12 doses. Once the maximum- tolerated dose (MTD) of the combination was determined, seven additional patients who had not been treated with either drug were evaluated to determine whether the addition of r-verapamil altered the pharmacokinetics of paclitaxel. Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression before receiving paclitaxel and after becoming refractory to paclitaxel therapy. Results: The MTD of the combination was 225 mg/m2 of r- verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion. Dose- limiting hypotension and bradycardia were observed in three of five patients treated at 250 mg/m2 r-verapamil. Fourteen patients received 32 cycles of r- verapamil at the MTD as outpatient therapy without developing cardiac toxicity. The median peak and trough serum verapamil concentrations at the MTD were 5.1 μmol/L (range, 4.1 to 12.7) and 3.2 μmol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR). Increased serum verapamil concentrations and cardiac toxicity were observed more frequently in patients with elevated hepatic transaminases and bilirubin levels. Hematologic toxicity from combined paclitaxel and r-verapamil was significantly worse compared with the previous cycle of paclitaxel without r- verapamil. In the pharmacokinetic analysis, r-verapamil delayed mean paclitaxel clearance and increased mean peak paclitaxel concentrations. Conclusion: r-Verapamil at 225 mg/m2 orally every 4 hours can be given safely with paclitaxel 200 mg/m2 by 3-hour infusion as outpatient therapy and is associated with serum levels considered active for Pgp inhibition. The addition of r-verapamil significantly alters the toxicity and pharmacokinetics of paclitaxel.",
author = "Tolcher, {A. W.} and Cowan, {Kenneth H} and D. Solomon and F. Ognibene and B. Goldspiel and R. Chang and Noone, {M. H.} and Denicoff, {A. M.} and Barnes, {C. S.} and Gossard, {M. R.} and Fetsch, {P. A.} and Berg, {S. L.} and Balis, {F. M.} and Venzon, {D. J.} and O'Shaughnessy, {J. A.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1200/JCO.1996.14.4.1173",
language = "English (US)",
volume = "14",
pages = "1173--1184",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

AU - Tolcher, A. W.

AU - Cowan, Kenneth H

AU - Solomon, D.

AU - Ognibene, F.

AU - Goldspiel, B.

AU - Chang, R.

AU - Noone, M. H.

AU - Denicoff, A. M.

AU - Barnes, C. S.

AU - Gossard, M. R.

AU - Fetsch, P. A.

AU - Berg, S. L.

AU - Balis, F. M.

AU - Venzon, D. J.

AU - O'Shaughnessy, J. A.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) and r-verapamil, the less cardiotoxic stereoisomer, in heavily pretreated patients with metastatic breast cancer. Patients and Methods: Twenty-nine patients refractory to paclitaxel by 3-hour infusion were treated orally with r- verapamil every 4 hours starting 24 hours before the same-dose 3-hour paclitaxel infusion and continuing far a total of 12 doses. Once the maximum- tolerated dose (MTD) of the combination was determined, seven additional patients who had not been treated with either drug were evaluated to determine whether the addition of r-verapamil altered the pharmacokinetics of paclitaxel. Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression before receiving paclitaxel and after becoming refractory to paclitaxel therapy. Results: The MTD of the combination was 225 mg/m2 of r- verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion. Dose- limiting hypotension and bradycardia were observed in three of five patients treated at 250 mg/m2 r-verapamil. Fourteen patients received 32 cycles of r- verapamil at the MTD as outpatient therapy without developing cardiac toxicity. The median peak and trough serum verapamil concentrations at the MTD were 5.1 μmol/L (range, 4.1 to 12.7) and 3.2 μmol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR). Increased serum verapamil concentrations and cardiac toxicity were observed more frequently in patients with elevated hepatic transaminases and bilirubin levels. Hematologic toxicity from combined paclitaxel and r-verapamil was significantly worse compared with the previous cycle of paclitaxel without r- verapamil. In the pharmacokinetic analysis, r-verapamil delayed mean paclitaxel clearance and increased mean peak paclitaxel concentrations. Conclusion: r-Verapamil at 225 mg/m2 orally every 4 hours can be given safely with paclitaxel 200 mg/m2 by 3-hour infusion as outpatient therapy and is associated with serum levels considered active for Pgp inhibition. The addition of r-verapamil significantly alters the toxicity and pharmacokinetics of paclitaxel.

AB - Purpose: We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) and r-verapamil, the less cardiotoxic stereoisomer, in heavily pretreated patients with metastatic breast cancer. Patients and Methods: Twenty-nine patients refractory to paclitaxel by 3-hour infusion were treated orally with r- verapamil every 4 hours starting 24 hours before the same-dose 3-hour paclitaxel infusion and continuing far a total of 12 doses. Once the maximum- tolerated dose (MTD) of the combination was determined, seven additional patients who had not been treated with either drug were evaluated to determine whether the addition of r-verapamil altered the pharmacokinetics of paclitaxel. Consenting patients had tumor biopsies for P-glycoprotein (Pgp) expression before receiving paclitaxel and after becoming refractory to paclitaxel therapy. Results: The MTD of the combination was 225 mg/m2 of r- verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion. Dose- limiting hypotension and bradycardia were observed in three of five patients treated at 250 mg/m2 r-verapamil. Fourteen patients received 32 cycles of r- verapamil at the MTD as outpatient therapy without developing cardiac toxicity. The median peak and trough serum verapamil concentrations at the MTD were 5.1 μmol/L (range, 4.1 to 12.7) and 3.2 μmol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR). Increased serum verapamil concentrations and cardiac toxicity were observed more frequently in patients with elevated hepatic transaminases and bilirubin levels. Hematologic toxicity from combined paclitaxel and r-verapamil was significantly worse compared with the previous cycle of paclitaxel without r- verapamil. In the pharmacokinetic analysis, r-verapamil delayed mean paclitaxel clearance and increased mean peak paclitaxel concentrations. Conclusion: r-Verapamil at 225 mg/m2 orally every 4 hours can be given safely with paclitaxel 200 mg/m2 by 3-hour infusion as outpatient therapy and is associated with serum levels considered active for Pgp inhibition. The addition of r-verapamil significantly alters the toxicity and pharmacokinetics of paclitaxel.

UR - http://www.scopus.com/inward/record.url?scp=9244232271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244232271&partnerID=8YFLogxK

U2 - 10.1200/JCO.1996.14.4.1173

DO - 10.1200/JCO.1996.14.4.1173

M3 - Article

VL - 14

SP - 1173

EP - 1184

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -